CorWave today touted 60-day study results from its preclinical study to evaluate its left ventricular assist device.
The study concluded that the company’s LVAD has the ability to provide chronic circulatory support with outstanding hemocompatibility.
“We were thrilled by the performance of the pump. This study bolsters the excellent hemocompatibility data from our previous trials, while confirming recent improvements in hemodynamic performance, anatomic fit, and the ventricular interface. We are grateful to our team and our pre-clinical testing partners for their efforts in assisting us to achieve this success,” senior director of translational and clinical research at CorWave Trevor Snyder said in a press release.
“This successful 60-day experiment is a key milestone toward bringing the device to clinical trials,” CEO Louis de Lillers said.
France-based CorWave raised $17 million in July last year to support its R&D program to develop its cardiac assistance pump into an LVAD.